CardioVascular BioTherapeutics to Present at Fourth Annual Emerging Technologies Symposium; World Renowned Cardiac & Thoracic Surgeon to Discuss New Treatment for No-Option Heart Patients.

LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced that Co-Founder and Chief Clinical Officer, Dr. Thomas Stegmann, the cardiac surgeon who pioneered the procedure upon which CVBT was founded, has been invited to present CVBT's clinical developments in cardiovascular therapies at the Fourth Annual Emerging Technologies Symposium. The conference is scheduled on July 18 and 19 at the Meydenbauer Center in Bellevue, Washington, and is part of the Sixth Annual Science-Innovation-Synergy ("SIS") 2006 course from July 18 to 22, 2006. The SIS conference focuses on issues related to cardiac, vascular and neurovascular diseases and is a forum for biotech scientists to interface with end-user physicians.

"CardioVascular BioTherapeutics is dedicated to researching, developing, and implementing cutting-edge treatment options for the more than 77 million people suffering from cardiovascular and other diseases resulting from lack of sufficient blood flow to organs and tissues," said Dr. Thomas Stegmann. "We are excited about our latest achievement in reaching a safety milestone in our Phase I clinical trial in which our drug candidate, with Cardio Vascu-Grow(TM) as its active ingredient, was injected in no-option heart patients to stimulate the growth of new blood vessels. We believe that increasing blood perfusion and oxygen supply to ischemic areas through the growth of new blood vessels, a process called angiogenesis, will result in a better quality of life for those suffering from vascular disease."

The event provides physicians and healthcare professionals a state-of-the-art perspective of the field and a glimpse into the future technologies and treatments in cardiac, vascular and neurological intervention. The Emerging Technologies Symposium, which is sponsored by the AHA, CRF, SCAI, Seattle Heart & Vascular Institute, Seattle Neuroscience Institute, and the Swedish Medical Center, is focused on the latest scientific developments in biotechnology.

About CardioVascular BioTherapeutics, Inc.

CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. Currently, the company is conducting two FDA-authorized clinical trials: one in the area of coronary artery disease in no-option heart patients, and one in the area of impaired wound healing seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral vascular disease of the legs and stroke recovery. Clinical trials in these two indications are planned to begin later this year in the U.S.A. A foreign clinical trial relating to chronic back pain believed to be caused by impaired or blocked arteries has also been initiated.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Cardio Vascu-Grow is a trademark of CardioVascular BioTherapeutics, Inc.